2011-07-02T08:18:19-05:00 2010-12-31 John A Epeneter PC 3 Russell Avenue Maynard MA 017541417 990 2010-01-01 522396428 Alzheimer's Disease Research Foundation ALZH 7812373800 34 Washington Street No 200 Wellesley MA 02481 Timothy W Armour 7812373800 2011-07-02 1 John A Epeneter 9788970741 2010 2016-02-24 21:20:13Z Cure Alzheimer's Fund Timothy W Armour 21 Sunset Road Weston MA 02493 4575982 0 X www.curealzfund.org X 2004 PA To fund targeted research with the highest probability of slowing, stopping or reversing Alzheimer's disease. 6 5 0 0 0 0 3339365 3983161 0 0 19523 -5755 200 0 3359088 3977406 2387914 3394263 0 0 320450 305410 0 0 237914 352099 382718 3060463 4082391 298625 -104985 3093146 3273140 34502 318937 3058644 2954203 X To fund targeted research with the highest probability of slowing, stopping or reversing Alzheimer's disease. 0 0 1200000 In 2010 Cure Alzheimer's Fund distributed $3,094,287 for research support projects. To read a more detailed report on our research see Cure Alzheimer's Fund's Scientific Report 2010.The Alzheimer's Genome Project, Massachusetts General Hospital, Dr. Rudy TanziThe Alzheimer's Genome Project is Cure Alzheimer's Fund core research effort. It has the objective of identifying all relevant Alzheimer's genes that have not yet been discovered, thereby identifying more targets for the development of therapeutic interventions. It is the largest family-based genome scan ever of a single disease. A milestone for this project was achieved in 2008 with the identification of new genes that confer risk for or protection against Alzheimer's. This accomplishment was recognized by TIME magazine and CNN as one of the top ten medical breakthroughs of the year.Prior to this project, there were 4 known Alzheimer's genes. Now CAF researchers have identified more than 120 candidate genes and have already confirmed the mechanisms of action of several of these, thereby readying them for drug discovery. Twenty five of the most important of the genes are undergoing detailed translational analysis.This effort represents some of the most important Alzheimer's breakthroughs in recent hisotry, as the genes will greatly faciliatate the development of effective therapies for the disease. Each newly identified gene offers fresh understanding of the pathology of the disease and holds promise for the development of therapeutic intervention. 300000 Abeta as an Anti-Microbial Agent; Rob Moir and Dr. Rudy Tanzi, Massachusetts General HospitalThis project explores a completely new and potentially very significant theory concerning the cause of Alzheimer's disease. The "Anti-Microbial Hypothesis" theorizes that Abeta has a positive function - protecting the brain from invading microbes and defending against bacteria. Initially this project was exclusively funded by CAF, but the subject is now also funded by a multi-million dollar grant from the National Insitutes of Health. 100000 Exploring mechanisms of neuroserpin regulation in Alzheimer's disease, University of Colorado, Nicholas SeedsOur recent studies have shown that the protease inhibitor neuroserpin, which ultimately leads to decreased breakdown of amyloid-beta and its accumulation, is 70% higher in the Alzheimer's Disease brain as compared to normal brain. We've also shown that deletion of the neuroserpin gene in an Alzheimer disease model mouse, restores normal cognitive behavior. Therefore, we will study why neuroserpin is up-regulated in Alzheimer's Disease, and will screen for small molecules that block neuroserpin action and may be useful therapeutic agents to prevent amyloid accumulation and cognitive loss in Alzheimer's Disease patients. 400000 Curcumin Collaborative Project, University of Pittsburgh and Massachusetts General Hospital, Dr. William Klunk and Dr. Rudy Tanzi.This collaborative project will identify and characterize novel curcumin-like derivatives for the treatment and prevention of Alzheimer's disease. The purpose of the study is to develop means of overcoming obstacles to rapid breakdown and creating methodologies for precisely delivering curcumin derivatives to appropriate locations within the brain. 100000 Brain Structure, Abeta Metabolism and Beehavior in Mice Deficient in Diabetes and Alzheimer's Associated SorCS1, Mount Sinai School of Medicine, Dr. Sam Gandy.Within the past five years, late onset Alzheimer's Disease and Type 2 Diabetes have been independently linked with the gene for a protein called SorCS1. This project's objective is to build on this early data to first better understand the link between AD and T2D, and second to point to new potential drug targets for treating both AD and T2D. 496502 Program service costs, such as an allocated portion of program salaries, fringe benefits, information and awareness, SAB/RC support, and similar direct program costs that have not been specifically allocated to the amounts of specific grant expenditures. 100000 Modulation of Abeta Deposition by Cell-Specific Mechanisms, University of Chicago, Dr. Sangram Sisodia.This project will employ a genetic strategy that allows for spatial-, temporal-, and cell-specific excision of a mutant PS transgene in order to examine cell autonomous versus non-cell-autonomous mechanisms of Abeta deposition. Researchers have strong preliminary studies to validate that the cre excision strategy works efficiently in mice and have the requisite cellular, biochemical and molecular tools to carry out the proposed studies. If specific cell types in the brain are shown to have an impact on Abeta deposition, investigations will expand to identify the cellular factor(s) responsible for the observed effects with the notion that strategies aimed at modulating the function of these molecules will be therapeutically efficacious in patients with AD. 250000 Novel Soluable Gamma-Secretase Modulators, Steven Wagner and Rudy Tanzi, University of California, San Diego and Massachusetts General Hospital.Building on in vitro characterization of a novel series of soluable gamma-secretase modulators (SGSMs) funded by Cure Alzheimer's Fund, the current project is a thorough pharmacological or in vivo examination of these molecules to identify the best or "lead" drug candidate. 100000 Passive Tau Immunotherapy for Treatment of Alzheimer's Disease, University of Pennsylvania, Dr. Virginia Lee.We propose a series of studies to rationally select candidate monoclonal antibodies (mAbs) that bind and neutralize transmissible misfolded tau species, with confirmatory testing of selected mAbs in a mouse model of pathological tau transmission. One or more selected mAbs will subsequently be tested in the established PS19 Tau transgenic (Tg) mouse model12, which develops forebrain tau inclusions, neuron loss and cognitive deficits13, to determine whether passive immunization results in an attenuation of tau-mediated neuropathology. 63851 Mouse Model for Non-Generic Alzheimer's Disease, University of California, San Digeo, Dr. Frank La Feria.The SAMP8 mouse model line is a model of accelerated senescence, and interestingly, develops sparse amyloid plaques, which is remarkable given the less amyloidogeneic properties of murine Ab. Hence, the research hypothesis for this project is that by introducing the more amyloidogenic human APP at the endogenous locus, researchers will be able to more robustly minic the onset of sporadic Alzheimer's disease, and thereby utilize this model for pre-clinical development and for widespread distribution to other investigators in the field. 100000 NMDA Receptors, University of California, San Diego, Roberto Malinow.The traditional signaling induced by NMDA-Rs is triggered by the Ca2+ ions that pass through the NMDA-R cannel. However, preliminary data indicate that blockers at the NR2B subunit, but not the NR1 subunit or the channel of the NMDA receptor prevent the synaptic effects of the NMDA receptor. These findings suggest that A-beta employs novel, non-ion flux NMDA-R signaling mechanisms to produce synaptic depression. These results may open up a new group of potential therapeutic targets for treatment of Alzheimer's disease. 100000 Anti-APOE Antibodies, Washington University, St. Louis, David Holtzman.In this project, the researchers hypothesize that targetng apoE, a component of amyloid plaques, can result in less Ab aggregation in the brain and decreased Ab-related pathology and that this treatment will have fewer side effects than the use of anti-Ab antibodies. The project will test this hypothesis in this proposal in the context of human apoE isoforms. 122336 Sustaining Support for the AlzGene, Max Planck Institute for Molecular Genetics, Lars Bertram.The AlzGene database is a revolutionary resource for Alzheimer's researchers providing data and meta-analyses from hundreds of genetic association studies in an easy-to-use, searchable, web-based database. This site allows researchers to post their findings and comment on other findings. It aggregates huge amounts of information that will help in the search for the genetic makeup of Alzheimer's. Currently, the database has more than 1,000 studies. The site also contains a continuously updated list displaying the genes most strongly associated with AD (on the website see "Top AlzGene Results"). Scientists interested in a particular gene can search for it in AlzGene to see what previous studies have reported, receiving a wealth of information in a very short amount of time. 40000 Peek and Treat Approach to Diagnosis, Treatment and Monitoring of Alzheimer's Disease, University Texas Health Science Center at Houston and University of Houston, Ananth Annapragada and Jason Eriksen.The objective of this project is to develop a nanotechnology platform that can simultaneously be used to diagnose and treat Alzheimer's. The work will explore how to develop multifunctional nanocarriers that contain both an imaging agent and a therpeutic agent and also will improve the binding capabilities of the nanocarrier allowing regulation of the release of therapeutic molecules to amyloid lesions. 100000 Design and Development of Novel ACAT Inhibitors for Alzheimer's Disease; Dora M. Kovacs, Massachusetts General Hospital.The third part of a study focusing on enzyme inhibitors that prevent or decrease the production of Abeta in the brain. This research explores the effectiveness of a drug approved for other uses. 18100 Microdialysis Supplement 1990789 3590789 1 1 0 1 0 0 0 0 0 0 1 0 0 0 0 0 1 0 0 0 0 0 1 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 X 6 5 1 0 0 0 0 0 0 1 1 0 0 0 1 1 1 1 1 1 1 0 MA AL AK AS AZ AR CA CO CT DE DC FM FL GA GU HI ID IL IN IA KS KY LA ME MH MD MI MN MS MO MT NE NV NH NJ NM NY NC ND MP OH OK OR PW PA PR RI SC SD TN TX UT VT VI VA WA WV WI WY X X Tim Armour 7812373800 c/o 34 Washington St Wellesley MA 02481 Jeffrey Morby 10.00 X 0 0 0 Jacqueline Morby 2.00 X 0 0 0 Henry McCance 5.00 X 0 0 0 Phyllis Rappaport 1.00 X 0 0 0 John S Lazo PhD 1.00 X 0 0 0 Timothy W Armour 40.00 X X X 177053 0 0 Katherine F Cutler 30.00 X 78112 0 0 255165 0 0 1 0 1 0 0 148500 3834661 598576 3983161 4161 4161 588660 598576 -9916 -9916 -9916 3977406 -9916 0 4161 3394263 3394263 255165 58844 92172 104149 50245 13208 21391 15646 4137 4137 1952 1952 34704 34704 38851 38851 2200 2200 7609 7609 2346 2346 10501 2132 8369 24000 24000 8601 5160 3441 20512 18339 2173 4051 4051 2383 2383 Information and awarene 57184 57184 SAB/RC support honorari 28470 28470 Loss on abandonment of 27101 27101 Social network 24300 24300 Board and executive mee 13126 13126 70690 15321 18579 36790 4082391 3590789 253688 237914 1093187 654165 1841227 2343857 71822 15267 22545 219843 7861 3810 28902 15088 34194 13814 465 386 21845 21998 3093146 3273140 23205 307585 11297 11352 34502 318937 X 2938936 15267 3058644 2954203 3093146 3273140 X -104985 544 X 0 1 1 X 0 X 3283332 3560203 3042089 3339366 4039719 17264709 3283332 3560203 3042089 3339366 4039719 17264709 7089876 10174833 23434 97016 74626 20020 -5755 209341 -498 -498 17473552 0.58230 0.56180 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 0 0 0 0 0 1 38851 0 0 38851 0 Explanation of Other Lobbying Activities: Part II-B, Line 1i: A registered lobbyist contacted various Congressional legislators for the purpose of encouraging increased funding of Alzheimer's disease research. 9798 5820 3978 19104 9268 9836 13814 Accrued payroll 9776 Accrued profit sharing contribution 1576 11352 3977406 4082391 -104985 544 544 -104441 4064743 544 30238 57500 88282 3976461 945 945 3977406 4112629 30238 30238 4082391 0 4082391 Description of Uncertain Tax Positions Under FIN 48: Part X: Income Taxes - CAF was determined to be exempt from federal income tax under provisions of Section 501(c)(3) of the Internal Revenue Code of 1986 (IRC) and has been classified as an organization that is not a private foundation as defined in Section 509(a)(3) of the IRC. Accordingly, no provisions for federal or state income taxes are required. CAF is required to recognize the financial statement impact of a tax position when it is more likely than not that the position will be sustained upon examination. Any interest and penalties recognized associated with a tax position would be classified as current in CAF's financial statements. Currently, the tax years ended December 31, 2007, 2008, and 2009 are open and subject to examination by the Internal Revenue Service and the Massachusets Department of Revenue. However, CAF is not currently under audit nor has CAF been contacted by any of these jurisdictions. Based on the evaluation of CAF's tax positions, management believes all positions taken would be upheld under an examination. Therefore, no provision for the effects of uncertain tax positions has been recorded for the year ended December 31, 2010. The adjustment on line 8 of Schedule D, Part XIV represents a reduction in pledges receivable from 2009 to 2010. 0 0 0 0 0 0 0 CAF funds the management and continued development of the revolutionary web-based database, AlzGene.org. BERLIN, BRANDENBURG, GERMANY 1 122336 Check 0 None Project budget 0 0 0 0 0 0 Explanation for Estimated Number of Recipients: Schedule F, Part III, Col (c): Max Plank Institute for Molecular Genetics, Lars Bertrum, Project Manager 1 Massachusetts General Hospital MGH Aging and Research Unit 114 16th Street Charlestown MA 02129 501c3 1200000 Continuation of Alzheimer's Genome Project Massachusetts General Hospital MGH Aging and Research Unit 114 16th Street Charlestown MA 02129 501c3 300000 Abeta as an Anti-Microbial Agent Massachusetts General Hospital MGH Aging and Research Unit 114 16th Street Charlestown MA 02129 501c3 100000 Design and Development of Novel ACAT Inhibitors for Alzheimer's DiseaseSpecificity and Mechanism of A-beta Oligomer Through Prior Protein Massachusetts General Hospital MGH Aging and Research Unit 114 16th Street Charlestown MA 02129 501c3 100000 Curcumin Collaborative Project University of Pittsburgh 3811 OHara Street Pittsburgh PA 15213 501c3 300000 Curcumin Collaborative Project The University of Chicago 947 E 58th Street Chicago IL 60637 501c3 100000 Modulation of Abeta Deposition by Cell-Specific Mechanisms The University of Chicago 947 E 58th Street Chicago IL 60637 501c3 100000 Exploring mechanisms of neuroserpin regulation in Alzheimer's disease University of San DiegoCA and MassGeneral Hospital 9500 Gilman Drive Mailcode 0624 La Jolla CA 92093 501c3 250000 Novel Soluable Gamma-Secretase ModulatorsContinuation of Alzheimer's Genome Project Trustees of University of Pennsylvania 3451 Walnut Street Philadelphia PA 191046205 501c3 100000 Passive Tau Immunotherapy for Treatment of Alzheimer's Disease Regents of University of Pennsylvania 3451 Walnut Street Philadelphia PA 191046205 501c3 63851 Mouse Model for Non-Generic Alzheimer's Disease Mt Sinai School of Medicine Dept of Neurology One Gustov L Levy Place Annenbeg 14-60 New York NY 10029 503c3 100000 Brain Structure, Abeta Metabolism and Behavior in Mice Deficient in Diabetes and Alzheimer's Associated SorCS1 Regents of University of California Dept of Molecular Biology and Chemistry Irvine CA 926973900 501c3 100000 NMDA Receptors Washington University School of Medicine Dept of Neurology 660 S Euclid Avenue Box 8018 St Louis MO 63110 501c3 100000 Anti-APOE AntibodiesAnti-APOE Antibodies Max Planck Institute for Molecular Genetics Ihnestrasse 63 Room 2041 Berlin DE 14195 501c3 122336 Sustaining Support for the AlzGene University of Houston & University of Texas Health Science Center 7000 Fannin Suite 600 Houston TX 77030 501c3 40000 Peak and Treat Approach to Diagnosis, Treatment and Monitoring of Alzheimer's Disease Washington University School of Medicine 660 S Euclid Avenue Box 8018 St Louis MO 63110 501c3 18100 Microdialysis Supplement Procedure for Monitoring Grants in the U.S.: Part I, Line 2: Schedule I, Part I, Line 2: 1. Cure Alzheimer's Fund (CAF) does not accept unsolicited proposals; all grant proposals are by invitation. 2. Each proposal is reviewed by: a. Chair of the CAF Research Consortium, a senior research scientist on the faculty of Harvard Medical School and Massachusetts General Hospital. If the proposal is approved by him, it goes to: b. The CAF Scientific Review Board, composed of five eminent research scientists at leading Alzheimer's research institutions in the United States. If that board approves the proposal, it then goes to: c. The Executive Committee of the CAF Board of Directors for final sign-off. 3. Once approved, a mid-year report is expected and is reviewed by the Chair of the Research Consortium. 4. At the end of the grant period (usually one year), a final report is submitted by the researcher and made available to the members of the Research Consortium for review and possible collaboration. 5. CAF is credited for support in any published papers resulting from the project. X X X X 0 0 0 0 0 0 0 0 0 Timothy W Armour 177053 0 0 0 0 0 0 0 0 0 177053 0 0 0 X 11 598576 average high and low X Services 1 30238 Invoice amount 0 0 1 Third Party Use: Part I, Line 32b: The organization uses a commercial broker to process and sell publicly traded securities. Form 990, Part VI, Section A, line 2 Jeffrey Morby and Jacqueline Morby are both directors and marriage partners. Form 990, Part VI, Section B, line 11 Jeffrey Morby and Phyllis Morby are both directors and marriage partners. Form 990, Part VI, Section B, line 12c The President regularly and consistently monitors compliance with conflicts of interest by requesting that all officers, directors, and founders sign the annual statement disclosing all interests that might conflict with any interest of the organization. Form 990, Part VI, Section B, line 15 Performance review and comparability data are submitted annually to executive committee for compensation approval for the President and all other employees. Form 990, Part VI, Section C, line 19 The governing documents, conflict of interest policy and financial statements are made available on the organization's website and upon request. Changes in Net Assets or Fund Balances: Form 990, Part XI, line 5: Net unrealized gains on investments: 544.